



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 08-10

March 03, 2008

Eisai Co., Ltd.

***Vasolan*[®] (Ischaemic Heart Disease Treatment) Received Approval
for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that *Vasolan*[®] Tablets 40mg (generic name: verapamil hydrochloride) received approval for the additional indications of the treatment of atrial fibrillation/flutter and paroxysmal supraventricular tachycardia. This approval makes *Vasolan*[®] the first oral form of calcium channel blockers approved for the treatment of tachyarrhythmia in Japan.

Vasolan[®] is a calcium channel blocker with coronary/peripheral vasodilator actions. It has been used to treat ischaemic heart disease for more than forty years. For many years, *Vasolan*[®] has been used to treat arrhythmia in the U.S. and European countries because of its beneficially effects on heart rate control in artial fibrillation/flutter and stopping/preventing paroxysmal supraventricular tachycardia. In Japan, *Vasolan*[®] for intravenous injection 5mg that contains the same active ingredients as the oral form tablet has been approved for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia). The additional indications approved today for the oral form of *Vasolan*[®] will provide a wider range of treatment options for patients who are suffering from tachyarrhythmia.

Atrial fibrillation is the most common tachyarrhythmia. Its risk increases with age, and medical need to treat atrial fibrillation becomes more critical in Japan's aging society. There are three general strategies to treat atrial fibrillation: rate control, rhythm control, and prevention of thromboembolic events. *Vasolan*[®] Tablets 40mg is beneficial in rate control.

This approval, together with Eisai's other related products including *Tambocor*[®] for the indication of tachyarrhythmia and *Warfarin*[®] as an anticoagulant, will enable Eisai to make further contributions to patients by offering treatment options for managing atrial fibrillation.

[Please see the following notes for the glossary and approved product information]

Contacts:

Corporate Communications Department

Eisai Co., Ltd.

81-3-3817-5120

<Notes to Editor>

Glossary

(1) Arrhythmia

Usually, a healthy adult has an average heart rate between 60 to 100 beats per minute (BPM). This rate can increase/decrease due to some factors. An abnormal heart rate of more than 100 BPM is called “tachyarrhythmia” and a low rate below 50 BPM is called “bradyarrhythmia” (slow arrhythmia), whereas the appearance of unexpected pulse is called “extrasystole”. In general, abnormal pulse conditions including the ones these described above are referred to as “arrhythmia”.

(2) Atrial fibrillation/flutter